IJAR - Indian Journal of Applied Research

Volume : VIII, Issue : V, May - 2018

Dr. Varsha Mandloi, Dr. Supriya Sharma, Dr. Abhishek Shrivastava, Dr. Arun Kumar Shrivastava

Introduction: The primary objective was to prevent delayed chemo induced nausea and vomiting (CINV). The primary

efficacy end point was complete response (CR) and improving quality of life (QOL).

Material and Method: This is a prospective, observational study conducted on 120 previously untreated histopathologically–proven patients of

ductal carcinoma of Breast from July 2015 to March 2016. In this study the patients were selected based on our inclusion criteria and each cohort

was composed of 40 east carcinoma diagnosed patients, each cohort receiving Oral Ondansetron 4 mg TDS was given in cohort 1; Oral

Granisetron 1 mg BD given to cohort 2 patients; and Oral Palonosetron 0.5 mg OD given to the cohort 3 from day 3 to day 7 post chemotherapy

for prevention of delayed CINV, and were asked to keep a vomiting diary , interviewed on telephone and on next follow up visit and then result

were graded according to the response obtained by each individual. Patients with history of allergy to 5HT–3 antagonists, any associated medical

condition causing nausea/vomiting were excluded.

Results: A total 120 patients were included in the study. In these study 57% patients in Ondanseteron cohort had complete Response, 84%

patients in Graniseteron cohort had complete Response and 64% patients in palonosetron cohort had complete response.

Conclusion: As compared to other 5HT3 receptor antagonists, Granisetron has better response in prevention of chemotherapy induced nausea

and vomiting in patients of ductal carcinoma east receiving Anthracyclines based chemotherapy.